Nurix Therapeutics Inc [NRIX] stock is trading at $18.93, up 2.99%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NRIX shares have gain 8.61% over the last week, with a monthly amount drifted -0.73%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nurix Therapeutics Inc [NASDAQ: NRIX] stock has seen the most recent analyst activity on January 08, 2026, when Morgan Stanley upgraded its rating to an Overweight but kept the price target unchanged to $36 for it. On October 21, 2025, Mizuho initiated with an Outperform rating and assigned a price target of $24 on the stock. Leerink Partners started tracking the stock assigning a Market Perform rating and suggested a price target of $16 on March 17, 2025. BTIG Research initiated its recommendation with a Buy and recommended $35 as its price target on December 10, 2024. BMO Capital Markets started tracking with an Outperform rating for this stock on December 06, 2024, and assigned it a price target of $35. In a note dated October 24, 2024, UBS initiated a Buy rating and provided a target price of $35 on this stock.
Nurix Therapeutics Inc [NRIX] stock has fluctuated between $8.18 and $22.50 over the past year. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $18.93 at the most recent close of the market. An investor can expect a potential return of 58.48% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
Nurix Therapeutics Inc [NASDAQ:NRIX] reported sales of 83.69M for the trailing twelve months, which represents a drop of -37.29%. Gross Profit Margin for this corporation currently stands at -1.63% with Operating Profit Margin at -3.19%, Pretax Profit Margin comes in at -2.92%, and Net Profit Margin reading is -2.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.54 and Total Capital is -0.61. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Nurix Therapeutics Inc’s Current Ratio is 5.35. As well, the Quick Ratio is 5.35, while the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 22.93, the price to book ratio is 3.91.
Transactions by insiders
Recent insider trading involved Ring Christine, Chief Legal Officer, that happened on Dec 18 ’25 when 3760.0 shares were sold. Officer, CHRISTINE RING completed a deal on Dec 18 ’25 to buy 7520.0 shares. Meanwhile, Chief Legal Officer Ring Christine sold 37600.0 shares on Nov 24 ’25.
